H1N1-Induced Venous Thromboembolic Events? Results of a Single-Institution Case Series

Dimakakos, Evangelos; Grapsa, Dimitra; Vathiotis, Ioannis; Papaspiliou, Aggeliki; Panagiotarakou, Meropi; Manolis, Evangelos N.; Syrigos, Konstantinos

doi:10.1093/ofid/ofw214

Cited by 19 publications

(19 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…COVID‐19 is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV2) and has contributed to significant morbidity and mortality, including the development of coagulopathy 2 . Similar thrombotic and thromboembolic events have occurred during other viral outbreaks, including severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome, and influenza A H1N1 3–7 …”

Section: Introductionmentioning

confidence: 99%

Emergence of institutional antithrombotic protocols for coronavirus 2019

Cohoon

Mahé

Tafur

et al. 2020

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

The coronavirus disease 2019 , first identified in December 2019 in Wuhan, China, is a major public health crisis with new infections increasing exponentially worldwide. 1 COVID-19 is an acute infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and has contributed to significant morbidity and mortality, including the development of coagulopathy. 2 Similar thrombotic and thromboembolic events have occurred during other viral outbreaks, including severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome, and influenza A H1N1. [3][4][5][6][7] Venous thromboembolism (VTE) (ie, deep vein thrombosis or pulmonary embolism [PE]) is a common complication of acute infectious diseases, which increase VTE risk 2-fold to 32-fold. 8-10 Survival among patients with incident and recurrent VTE is significantly reduced, especially after PE. 11 Hospitalized patients with acute medical illness, including infections such as pneumonia, are at increased risk of VTE, both in-hospital and for an extended period of time (up to 45 days) after hospital discharge. 8,9,[12][13][14][15][16] Despite this well-established association, 8-10 there are few data specifically addressing VTE in patients recently hospitalized with COVID-19 infections. 17,18 Indeed, infection-associated VTE might account for a substantial burden of incident or recurrent VTE among those with COVID-19.In addition, small-vessel hyaline thrombus formation has been described in autopsies of patients with COVID pneumonia. 19 There is increasing concern that mortality seen across all age groups may be secondary to PE, as 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is recently reported. PE was the most frequent thrombotic complication and contributed to 81% of thrombotic complications. 20 To improve outcomes, targeted prophylaxis efforts to improve coagulopathy and reduce incident VTE in patients with acute infectious diseases, specifically COVID-19, may be advantageous.Currently, VTE prophylaxis duration is mainly limited to the period of hospitalization, 21 but most VTE events occur within the first month following hospital discharge. 22 Recent data support the finding that an elevated D-dimer (>2× upper limit of normal [ULN]) is anThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

show abstract

Section: Introductionmentioning

confidence: 99%

Emergence of institutional antithrombotic protocols for coronavirus 2019

Cohoon

Mahé

Tafur

et al. 2020

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…VTEs and hypercoagulability have been reported previously in severe respiratory tract infections such as influenza [6,7]. It is believed that respiratory viruses might play a major role in the coagulation cascade.…”

Section: Discussionmentioning

confidence: 98%

Pulmonary embolism: A complication of COVID 19 infection

Akel

Qaqa

Abuarqoub

et al. 2020

Thrombosis Research

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

“…This case was a 36-year old previously healthy female who developed measles–induced ARDS and PE with hemodynamic instability. The interplay between viruses and pro-coagulant state has been previously reported; influenza has been associated with acute coronary syndromes [ 27 ] and possibly de novo PE in the absence of deep venous thrombosis [ 28 ], while similar cases have also been reported with other viral infections [ 29 ]. Apart from obesity, our patient did not have any other risk factors for PE, in agreement with a recently reported pediatric case [ 30 ].…”

Section: Discussionmentioning

confidence: 99%